International Journal of Hematology and Oncology 2021, Vol 31, Num 4 Page(s): 061-069
RESULTS OF ADJUVANT CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF) COMBINATION TREATMENT IN PREMENOPAUSAL STAGE I-IIIA BREAST CANCER PATIENTS

M. KADRİ ALTUNDAĞ1, ŞUAYİB YALÇIN1, EŞMEN BALTALI1, YAVUZ ÖZIŞIK1, NİLÜFER GÜLER1, İSMAİL ÇELİK1, OSMAN ABBASOĞLU1, DEMİR ALİ ONAT1, İ. LALE ATAHAN1, GÜLTEN TEKUZMAN1

Hacettepe Üniversitesi Onkoloji Enstitüsü

Keywords: breast cancer, premenopusal, cmf chemotherapy
In this study premenapausal stage I-IIIA breast cancer patients who had been treated with adjuvant CMF polychemotherapy protocols and had been followed at the Department of Oncology in Hacettepe University School of Medicine between 1985-1999 were included. Patients were evaluated for disease free and overall survival and toxicity. Median age of all patient were 42 (range: 23-54) years. At the time of diagnosis, 25 (12.6%) patients were at under the age 35 and the other 174 (%87.4) were 35 or higher. Median follow-up time was 45 (range:1-165) months. According to TNM classification 33, 153 and 13 of all the patients were at stage I, II and IIIA respectively. There was a statistically significant association between overall and disease free survival and stage, tumor size, number of positive lymph node. Most frequently seen toxicities were grade 1-3 nausea-vomiting (33%) and alopecia (19.5%). CMF chemotherapy regimen was tolerated well and there was no interruption of the treatment due to chemotherapy. We concluded that CMF polychemotherapy was well tolerated, safe and effective therapy for the adjuvant treatment of breast cancer.